|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples显示文摘瞄准:比较胰腺的腺癌织物标本的基因表示侧面,胰腺的人和腺癌和白血病房间线和正常的胰取样以便区分差别的冒号表示了基因并且在内视镜的指导超声的好针渴望( 指导EUS 的 FNA )由量的即时 RT-PCR ( RT-QPCR )验证基因的一个子集的微分表示标本。方法:包含 1176 基因的商业地奉献的癌症 cDNA 宏数组(地图集人癌症 1.2 ) 被使用。不同统计途径(层次聚类的、主要部件分析(PCA ) 和 SAM ) 被用来分析表示数据。RT-QPCR 和免疫组织化学的研究被用于结果的确认。结果:RT-QPCR 验证了 LCN2 的增加的表示(lipocalin 2 ) 并且第一次在恶意的胰的小块地(织物类型 plasminogen 使活跃之物或 tPA ) 同样与正常相比胰。Immunohistochemical 分析证实了在癌入侵的管的上皮细胞局部性的 LCN2 蛋白质的增加的表示。在与胰腺的腺癌从病人通过指导 EUS 的 FNA 获得的 12 件样品的小块地和 LCN2 抄本的分析与在正常纸巾发现的那些比较显示出显著地增加的表示层次,显示高质量的 RNA 的足够的数量能与这种技术被获得。结论:表示介绍是一个有用方法识别简历标记和潜在的目标基因。在胰腺的癌症的指导 EUS 的 FNA 样品的分子的分析为胰腺的腺癌的诊断作为珍贵策略出现。 | Henrik Laurell Michèle Bouisson Philippe Berthelémy Philippe Rochaix Sébastien Déjean Philippe Besse Christiana Susini Lucien Pradayrol Nicole Vaysse Louis Buscail | 2006 | World Journal of Gastroenterology2006，12，21： | 5 |
| 2 | MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer显示文摘Despite tremendous efforts from scientists and clinicians worldwide, pancreatic adenocarcinoma(PDAC) remains a deadly disease due to the lack of early diagnostic tools and reliable therapeutic approaches. Consequently, a majority of patients(80%) display an advanced disease that results in a low resection rate leading to an overall median survival of less than 6 months. Accordingly, robust markers for the early diagnosis and prognosis of pancreatic cancer, or markers indicative of survival and/or metastatic disease are des-perately needed to help alleviate the dismal prognosis of this cancer. In addition, the discovery of new therapeutic targets is mandatory to design effective treatments. In this review, we will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC. | Marion Gayral Sébastien Jo Naima Hanoun Alix Vignolle-Vidoni Hubert Lulka Yannick Delpu Aline Meulle Marlène Dufresne Marine Humeau Maёl Chalret du Rieu Barbara Bournet Janick Sèlves Rosine Guimbaud Nicolas Carrère Louis Buscail Jérome Torrisani Pierre Cordelier | 2014 | World Journal of Gastroenterology2014，20，32： | 4 |
| 3 | Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer显示文摘Pancreatic ductal adenocarcinoma remains one of the most deadly types of tumor. Endoscopic ultrasoundguided fine-needle aspiration(EUS-FNA) is a safe, cost-effective, and accurate technique for evaluating and staging pancreatic tumors. However, EUS-FNA may be inconclusive or doubtful in up to 20% of cases. This review underlines the clinical interest of the molecular analysis of samples obtained by EUS-FNA in assessing diagnosis or prognosis of pancreatic cancer, especially in locally advanced tumors. On EUS-FNA materials DNA, mRNA and miRNA can be extracted, amplified, quantified and subjected to methylation assay. Kras mutation assay, improves diagnosis of pancreatic cancer. When facing to clinical and radiological presentations of pseudo-tumorous chronic pancreatitis, wildtype Kras is evocative of benignity. Conversely, in front of a pancreatic mass suspected of malignancy, a mutated Kras is highly evocative of pancreatic adenocarci-noma. This strategy can reduce false-negative diagnoses, avoids the delay of making decisions and reduces loss of surgical resectability. Similar approaches are conducted using analysis of miRNA expression as well as Mucin or markers of invasion(S100P, S100A6, PLAT or PLAU). Beyond the diagnosis approach, the prediction of response to treatment can be also investigated form biomarkers expression within EUS-FNA materials. | Barbara Bournet Marion Gayral Jérme Torrisani Janick Selves Pierre Cordelier Louis Buscail | 2014 | World Journal of Gastroenterology2014，20，31： | 3 |
| 4 | MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions显示文摘 | du Rieu Ma?l Chalret Torrisani Jér?me Selves Janick Al Saati Talal Souque Anny Dufresne Marlène Tsongalis Gregory J Suriawinata Arief A Carrére Nicolas Buscail Louis Cordelier Pierre | 2010 | Clinical Chemistry2010，，： | 1 |
| 5 | Interventional Endoscopic Ultrasound in Pancreatic Diseases显示文摘 | Louis Buscail Patrick Faure Barbara Bournet Janick Selves Jean Escourrou | 2006 | Pancreatology . 2006 (1-2)2006，，： | 1 |
| 6 | Simplified identification of Lynch syndrome: A prospective, multicenter study显示文摘 | Delphine Bonnet Janick Selves Christine Toulas Marie Danjoux Jean Pierre Duffas Guillaume Portier Sylvain Kirzin Laurent Ghouti Nicolas Carrère Bertrand Suc Laurent Alric Karl Barange Louis Buscail Thierry Chaubard Kamran Imani Rosine Guimbaud | 2012 | Digestive and Liver Disease2012，，6： | 1 |
| 7 | Antiproliferative effect of somatostain and anologys显示文摘 | Corinne Bousquet Elena Puente Louis Buscail | 2001 | Chemotherapy2001，47，2： | 1 |
| 8 | Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis显示文摘 | Yannick Delpu Naima Hanoun Hubert Lulka Flavie Sicard Janick Selves Louis Buscail Jerome Torrisani Pierre Cordelier | 2011 | Current Genomics2011，，1： | 1 |
| 9 | Antiproliferative effect of somatostain and anologys 显示文摘 | Corinne Bousquet Elena Puente Louis Buscail | 2001 | Chemothrapy2001，47，2： | 1 |
| 10 | Microscopic examination of bile directly collected during endoscopic cannulation of the papilla显示文摘 | Dr. Louis Buscail MD Jean Escourrou MD Michel Delvaux MD PhD Rosine Guimbaud MD Thierry Nicolet MD Jacques Frexinos MD André Ribet MD | 1992 | Digestive Diseases and Sciences1992，，1： | 1 |
| 11 | Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas显示文摘AIM:To compare characteristics and outcomes of resected and nonresected main-duct and mixed intraductal papillary mucinous neoplasms of the pancreas(IPMN).METHODS:Over a 14-year period,50 patients who did not undergo surgery for resectable main-duct or mixed IPMN,for reasons of precluding comorbidities,age and/or refusal,were compared with 74 patients who underwent resection to assess differences in rates of survival,recurrence/occurrence of malignancy,and prognostic factors.All study participants had dilatation of the main pancreatic duct by ≥ 5 mm,with or without dilatation of the branch ducts.Some of the nonsurgical patients showed evidence of mucus upon perendoscopic retrograde cholangiopancreatography or endoscopic ultrasound and/or after fine needle aspiration.For the surgical patients,pathologic analysis of resected specimens confirmed a diagnosis of IPMN with involvement of the main pancreatic duct or of both branch ducts as well as the main pancreatic duct.Clinical and biologic follow-ups were conducted for all patients at least annually,through hospitalization or consultation every six months during the first year of follow-up,together with abdominal imaging analysis(magnetic resonance cholangiopancreatography or computed tomography) and,if necessary,endoscopic ultrasound with or without fine needle aspiration.RESULTS:The overall five-year survival rate of patients who underwent resection was significantly greater than that for the nonsurgical patients(74% vs 58%; P =0.019).The parameters of age(< 70 years) and absence of a nodule were associated with better survival(P < 0.05); however,the parameters of main pancreatic duct diameter > 10 mm,branch ductdiameter > 30 mm,or presence of extra pancreatic cancers did not significantly influence the prognosis.In the nonsurgical patients,pancreatic malignancy occurred in 36% of cases within a mean time of 33 mo(median:29 mo; range:8-141 mo).Comparison of the nonsurgical patients who experienced disease progression with those who did not progress showed no significant differences in age,sex,symptoms,subtype of IPMN,or follow-up period; only the size of the main pancreatic duct was significantly different between these two sub-groups,with the nonsurgical patients who experienced progression showing a greater diameter at the time of diagnosis(> 10 mm).CONCLUSION:Patients unfit for surgery have a 36% greater risk of developing pancreatic malignancy of the main-duct or mixed IPMN within a median of 2.5 years. | Mathieu Daudé Fabrice Muscari Camille Buscail Nicolas Carrère Philippe Otal Janick Selves Louis Buscail Barbara Bournet | 2015 | World Journal of Gastroenterology2015，21，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员